Over the past five years, the Food and Drug Administration (FDA) has approved a combination regimen of anti-programmed death ligand-1 (PD-L1) atezolizumab and anti-vascular endothelial growth factor (VEGF) bevacizumab as the first-line therapy for HCC [4, 5]. This evidence concerns the gene CD274 and hepatocellular carcinoma.